Jiangsu Hengrui Pharmaceuticals(600276.SH) received acceptance of the application for the marketing license of SHR4640 tablets.

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that the company has received the "Acceptance Notification" issued by the National Medical Products Administration. The company's application for the market approval of SHR4640 tablets has been accepted by the national drug regulatory authority. The drug is intended for the long-term treatment of primary gout with hyperuricemia.